Association of MSS/MSI-RNF43 molecular subtypes and clinical outcome of metastatic BRAF-V600E colorectal cancer patients treated with anti-BRAF/EGFR ± combinatorial therapies

被引：0
|
作者：
Elez, E. [1 ]
Ros, J. [2 ]
Randon, G. [3 ]
Lonardi, S. [4 ]
Cremolini, C. [5 ]
Pietrantonio, F.
Tabernero, J. [1 ,6 ]
Toledo, R. [1 ]
机构：
[1] Vall dHebron Inst Oncol, Barcelona, Spain
[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Med Oncol, Barcelona, Spain
[3] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[4] Veneto Inst Oncol IRCCS, Med Oncol, Padua, Italy
[5] Univ Pisa, Azienda Osped Univ Pisana, Unit Med Oncol, Dept Translat Res & New Technol Med & Surg, Pisa, Italy
[6] Vall dHebron Univ Hosp, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.04.449
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O-8
引用
收藏
页码：S382 / S382
页数：1
相关论文
共 50 条
  • [21] A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer
    Day, Fiona
    Muranyi, Andrea
    Singh, Shalini
    Shanmugam, Kandavel
    Williams, David
    Byrne, David
    Pham, Kym
    Palmieri, Michelle
    Tie, Jeanne
    Grogan, Thomas
    Gibbs, Peter
    Sieber, Oliver
    Waring, Paul
    Desai, Jayesh
    TARGETED ONCOLOGY, 2015, 10 (01) : 99 - 109
  • [22] A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer
    Fiona Day
    Andrea Muranyi
    Shalini Singh
    Kandavel Shanmugam
    David Williams
    David Byrne
    Kym Pham
    Michelle Palmieri
    Jeanne Tie
    Thomas Grogan
    Peter Gibbs
    Oliver Sieber
    Paul Waring
    Jayesh Desai
    Targeted Oncology, 2015, 10 : 99 - 109
  • [23] Influence of sex on safety and efficacy in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with encorafenib-cetuximab plus /-binimetinib (E-C plus /-B)
    Montana, F. J. Ros
    Navarro, V.
    Comas, R.
    Rodriguez, A. Garcia
    Gomez, D.
    Gonzalez, N. Saoudi
    Vicente, P.
    Cuadra, J. L.
    Paez, D.
    Alonso, V.
    Martinez, A. Hernandez
    Valbuena, D. E. Lopez
    Argota, I. Baraibar
    Ballabrera, F. Salva
    Tabernero, J.
    Fernandez, M. E. Elez
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S707 - S707
  • [24] Clinicopathological features, efficacy of anti-EGFR therapy, and survival outcomes in patients with BRAF non-V600 mutated metastatic colorectal cancer.
    Kotani, Daisuke
    Mondaca, Sebastian
    Parikh, Aparna
    Bando, Hideaki
    Van Seventer, Emily
    Taniguchi, Hiroya
    Yoshino, Takayuki
    Corcoran, Ryan Bruce
    Yaeger, Rona
    Ebi, Hiromichi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [25] BRAF V600E and survival benefit of anti-EGFR monoclonal antibody (mAb) therapy for metastatic colorectal cancer (mCRC): A meta-analysis.
    Sorich, Michael
    Rowland, Andrew
    Dias, Mafalda
    McKinnon, Ross Allan
    Kichenadasse, Ganessan
    Wiese, Michael
    Karapetis, Christos Stelios
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] BRAF V600E Mutation as a Predictive Factor of Anti-EGFR Monoclonal Antibodies Therapeutic Effects in Metastatic Colorectal Cancer: a Meta-analysis
    Qi Wang
    Wei-guo Hu
    Qi-bin Song
    Jia Wei
    Chinese Medical Sciences Journal, 2014, 29 (04) : 197 - 203
  • [27] Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)
    Atreya, Chloe Evelyn
    Van Cutsem, Eric
    Bendell, Johanna C.
    Andre, Thierry
    Schellens, Jan H. M.
    Gordon, Michael S.
    McRee, Autumn Jackson
    O'Dwyer, Peter J.
    Muro, Kei
    Tabernero, Josep
    van Geel, Robin
    Sidhu, Roger
    Greger, James G.
    Rangwala, Fatima A.
    Motwani, Monica
    Wu, Yuehui
    Orford, Keith W.
    Corcoran, Ryan Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] Encorafenib plus cetuximab treatment in BRAF V600-Emutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series
    Hafliger, Emilie
    Boccaccino, Alessandra
    Lapeyre-Prost, Alexandra
    Perret, Audrey
    Gallois, Claire
    Antista, Maria
    Pilla, Lorenzo
    Lecomte, Thierry
    Scartozzi, Mario
    Soularue, Emilie
    Salvatore, Lisa
    Bourgeois, Vincent
    Salati, Massimiliano
    Tougeron, David
    Evesque, Ludovic
    Vaillant, Jean-Nicolas
    El-Khoury, Reem
    Lonardi, Sara
    Cremolini, Chiara
    Taieb, Julien
    EUROPEAN JOURNAL OF CANCER, 2022, 168 : 34 - 40
  • [29] BEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC)
    Huijberts, S.
    Schellens, J. H. M.
    Elez, E.
    Cuyle, P-J.
    Van Cutsem, E.
    Yaeger, R.
    Fakih, M.
    Montagut, C.
    Peeters, M.
    Desai, J.
    Yoshino, T.
    Ciardiello, F.
    Wasan, H.
    Grothey, A.
    Maharry, K.
    Gollerkeri, A.
    Kopetz, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [30] Cetuximab rechallenge in RAS, BRAF, EGFR-ECD wild type metastatic colorectal cancer (mCRC) patients treated with anti-EGFR therapies in first line: The CITRIC study
    Santos Vivas, C.
    Salva, F.
    Fernandez-Rodriguez, C.
    Alonso Orduna, V.
    Losa, F.
    Paez, D.
    Vidal, J.
    Salud, A.
    Ribera Fernandez, P.
    Safont Aguilera, M.
    Tarazona, N.
    Hernandez-Yague, X.
    Layos Romero, L.
    Garcia-Carbonero, R.
    Rivera, F.
    Alvarez Gallego, R.
    Bellosillo, B.
    Montagut, C.
    ANNALS OF ONCOLOGY, 2022, 33 : S291 - S291
12345